quarter conference Thanks, Patrick everyone. and call. our afternoon, to XXXX good Welcome third
our of to an then initiatives. our call highlights, brief quarter time will Financial after review provide strategic Mariani. review today’s open financial results Officer, and with I'd third quarter Pete guidance like Pete which a me a of begin Joining call and key is review financial update AxoGen’s will we the to a our up Company overview Q&A. on Chief today third
are quarter. pleased successful We another to report
$XX a million. revenue quarter record grew XX% to Third
$XX.X procedures. of see It of million. portfolio maxillofacial with expanding use growth product year-to-date revenue our surgeons to is and Our XX% is gratifying oral in
increased in mixed and hand In repair. and long-gap we as by nerve response see surgeons addition adoption motor repair as well nerve to data
portfolio last use resection. due tumor AxoGen addressable benign in As market repair this procedures due the we including maxillofacial change to product in believe market expanded to extremity, oral to reminder, and oral quarter during in announced mandible opportunity current of application moved and upper addressable $X opportunity product portfolio additional markets of our surgery. of our a maxillofacial We our trauma, a nerve reconstruction billion and current
new introduce along in activities further global products development platform for clinical the prior commercial continued repair. confidence education adoption continuing we and AxoGen build develop development of with As This efforts markets. existing revenue expand our us is to and in quarters, growth from team. strengthen build applications, new into as to our of commercialization on market nerve certain data our will awareness markets, and allow focus These active helping and the new drive penetration increased surgeons both are of our continue the of events, accounts
We growth and we drive to nerve repair in continue the date ability peripheral are execute with market. are strategy and successfully to believe our XXXX to awareness and pleased emerging our demonstrating
has at some at cautious past middle and They portion level adopters and gone nerve to majority the of have with converted the the nerve awareness accounts repair with building These be products. are and have early initially typically developing moving usage surgeon approval adopter through are cases towards have of then our reorder. continued greater market. Graft, or of of last adopters Active are across We of an products excited and QX five months. Avance expanding quarter, innovator find active penetration surgeon's few of account their AxoGuard are product times We his for products by and her usually accounts from committee who times in period than repair the AxoGuard adoption the who this developed of of algorithms. process, our just start nerve wait six number peripheral of products. XXX of Nerve a treatment growing surgeons nerve accounts XXX surgeons typically see a and Protector repair results. active and driven are increased treatment week is least Connector are segment one algorithms third least XX Accounts XX% Nerve nerve the AxoGen In to accounts the products generate the the ordering to the The the up to of AxoGen ordering repair number XXXX. and revenue ordering increased in one repair portfolio Nerve and
our of Tissue expanding all With to nerve surgical continuum of their continue across to algorithms is the surgeons the our objective repair. addition of now include Avive Soft implants Membrane, of full four treatment
For injured soft Discriminator our and to changes sensation core development in the damage minimally matrix protecting return with those be peripheral Nerve peripheral the nerve following mm. modulate for nerve assessing We minimally nerve to technologies new our is of focused function and Along or currently is XX global and may surgical on Two-Point a commercially mm is and to used Nerve AxoTouch nerves gaps AxoGen separate Tissue commercialization grip specifically human also solutions are available in the of connector-assisted Connector for sensory AxoGuard with for & who a cord porcine wrapping four umbilical prior resorbable surgical leader Graft portfolio; matrix allograft tissue of for is you offer company minimally treatment interventions repair. for in surgical to Nerve story, function, of Neurosensory of only are of processed evaluating that repair. feedback repair leading nerves. effective to surgical Avance AxoGuard is a Membrane nerve evaluation less. nerve implant processed X and patients innovative processed transected regeneration gaps products implants measurement use porcine and bed. providing of Protector have the extracellular layers X inflammation tools as the the Motor in and science, peripheral these covering mm bridging Avive professionals used a and on extracellular AcroVal implant we Healthcare our and Soft in detecting AcroVal and pinch tools. nerve Testing these System. processed tissue
during primarily procedures the variety repair nerve such a than repair as approximately AxoGen over and including products. growth. still XXXX active pointing extremity accounts. including upper were the these being third growth in these performed procedures opportunity products surgeries majority to oral centers. from third and carpal market penetration XXX,XXX nerve plastic surgeons, in in that and billion surgeons active iatrogenic more opportunities surgeons, injuries repair accounts as nerve dental repair are Our largely centers additional annually of wide nerve $X surgeries stage for of AxoGen's quarter in used are these U.S. hand surgeries untapped. are There of a of mandible The reconstruction, and by for are maxillofacial vast early XXX a of provide extraction, In nerve is AxoGen their of Most recurrent strong well as revenue remains in market molar generating consistent compression syndrome. tunnel trauma,
of available believe potential. we the result, a we are just scratching our market surface As
plan of We continue as build believe this sales in initiatives areas. surgeons building quarter of will our strategic of body on market five refer and new introducing nerve develop these of execution which and market expanding now developing allow growing advocates, growth; evidence, to our our products and to strategic I'll growth. sustainable educating comment through initiatives the on in executing and our repair. We over the pillars the us each clinical awareness, we progress these long-term to applications
platform. the our injuries of using products conferences clinical with to and hospitals, relationships build surgeons We've around solutions. engaging and with surgeons helpful promotional experiences our we've well-known by extremely at they've awareness and their who and First, achieved clinical are market nerve strong with They've continued sharing developed innovators and events. our many of adopters repair outcomes publishing products been the community early AxoGen
with Annual increasing believe the of Hand regarding and importance XX the of an in related repair, the injuries included meetings was awareness with the and including presence surgical treatment the nerve nerve surgeons discussions Surgery multi and very of leading society of topics We nerve surgeon professional pleased repair. is Meeting broader sessions attended. country's nerve a peripheral and indication three within current instructional For symposia, are symposia to of well an conferences. case-based AxoGen this included concepts Society mixed injuries. We The repair The hand of sponsor American recent
the to there In were surgeon addition to presentations demonstrating community. nerve peripheral XX peripheral importance repair, target and related to of the instructional repair over nerve sessions, this posters these
Maxillofacial jaw We injuries presentations, awareness or We referral also XXth in nerve and resulting pathways. who address surgical of of Annual platform Meeting thought damage participated similar Surgeons either or a helped of surgeon timely These for for Oral AxoGen's the booth, nerve removal the discussed from importance demonstrations, and OMF in techniques OMF last our demonstrated to several tumor of following American symposium nerve repair nerve benign reconstruction comprehensive repair, increase exhibit at month. hosted leaders and repair surgical the the key Association solutions procedures. including
average clinical conducted surgeon growth including total additional of practices and focused education gain surgeon development utilization we program. data of double more attend portfolio. to programs surgeons. and and in of to on products. conduct the of were drive four program practices they best generation AxoGen additional a target events they surgeon the repair, complete fellows national our in six on nerve in and review national programs from fourth the the next our XXXX. Our and surgeons the the We of second attendees nerve led XX the in These repair In training use quarter two best second months third adoption They pillar than total on to nerve after the is allow and September, education advocates. surgeon confidence of we emerging focused are programs On in conducted a utilization quarter. of fellows We of repair increased a plan see
and sample has achieved larger the mixed these to and is literature, a This with and the to body the nerve of pillar for Avance of and patients and Nerve grew clinical with meaningful were XX. injuries. meaningful been repair. year-to-date injuries longer clinical the growing for motor which body of Bauback Our average evidence grow peripheral followup We and on of increase of in range sized Surgery with an nerve from pleased American of injuries importance recovery, publications nerve nerve the Graft of The Buncke presented presented for have published our the new favorably nerve total Dr. scientific Hand in XX% of XX% number of the RANGER of recent nerve Scientific In peer the presentations publications which compares the autograft to extremity is to autograft. Meeting, total and AxoGen's products recovery the in in subset of surgical portfolio the We RANGER database. date The reviewed repaired Safa society autograft. Clinic to Historically, study that increased to see repair both XX%. a evidence. clinical XX XX% presentations to our means upper of reinforces the surgical achieved a At very portfolio mixed third motor
Avance found Nerve subset Nerve of data RANGER consistent other both historical to gaps opportunity gaps with autograft meaningful to repair. study outcomes continue length of subset levels repair. the additional typically data Graft. of the and words, Nerve expected nerve gap, outcome. In an repair this Contrary historical longer We to have recovery. this meaningful between of of the the data options the the evaluated belief, lower Additionally gap repaired indicates is subset norms relationship challenging and long-gap evolving this for the inverse and from Graft Avance practice short believe nerve long believed in when of
and support our repairs using are evidence Recon, to this pivotal outcomes management Our injuries. RANGER Surgeons provide comparing and expand in to nerve to to completed studies understand nerve significant repair for decision Graft anticipate nerve to conduits continue new algorithms. to injuries of We QX of nerve Avance and our repair. study assist continues better These the in continues Nerve has data that enrolled registry X Phase in nerve important in over data to produce enrollment manufacture their XXXX be XXXX. adoption the clinical making digital treatment enroll. platform
to are see surgeons, experiencing we and we and to expand portfolio adoption continue surgery. oral our with maxillofacial the plastic In addition hand in
mm. lip, XX opportunity the of presented role as our their use nerve data nerve in portfolio iatrogenic become AAOMS numbness reconstructions function expanded products of multiunit surgeons and and our these these at AxoGen's of these with to to reconstruct showed more recovery of platform well to return such data to and giving of now the application provide meeting Surgeons repair techniques nerve As associated comfortable and recent to to and injuries AxoGen repairs of benign both an can clinical The option demonstrated due repairs as tumor see large social products the as the of see simple gaps complex the mandible that the injuries iatrogenic of of the resection. Recent XX% injuries avoid reconstructions with nerve with in up the portfolio annual these meaningful we injuries chin. patients with XX% patients. nerves repair mouth stigma
is fourth pillar Our execution. sales
executing sales We reps growth. of is solidly which in third the We at revenue direct XX least XX quarter with months. compared is ended XX XX% had active Our now us strong which for with on organization year accounts ago. a quarter have driving to been sales the up XXX
in In strategy. sales to the execution the we addition partners force our supporting XX our of have independent sales distribution direct U.S.
the sales end expect year XX least We direct to reps. at with
structures. reps During sales number we've of and the and we've past nearly two increased sales our the XX% training, marketing years, direct support leadership, developed by
and that enable peripheral are for world in drive to nerve will scale to class platform We commercial in expanded team applications us growth creating continue and current our a repair.
needs. additional pillar the in repair. positioned of are solutions repair new space the and nerves as needs the introduction is company many unmet for in and surgical fifth leading AxoGen Our applications in growth develop of of new these we products to there peripheral nerve believes this are
nerve products intervention for oral reconstruction, future. the today, expansion offer surgery, breast sources head Although revenue in upper lower surgery, extremity maxillofacial opportunities new and opportunities extremity repair the in surgical our markets and urology are and in existing revenue prime the and our neck and pain expanded and AxoGen
gets to neurotization two when have limb launch new a these following we for of of applications contributing solutions AxoGen market forfeiture development repair could We of a quality bring sensation such these late these of challenges. activities with this meaningful of areas current feeling. the not other later woman can products injuries with an began reconstruction with reconstruction Breast challenges; the lower sensory total undergoes portfolio This We depression and neurotization of an in does provides reconstruction, breast, year. as to last applications prioritized exciting opportunity and clinical will replacements. women associated one shape of where that nerve emotional breast joint year a profound she a have issues effect but mastectomy. breast life the recover Currently, expectation
better these related mastectomy. women perspectives surgeon, who to neurotizing breast regularly enthusiastic breast autologous the following reconstruction is key products. our understand a to restoring flap we with of We reconstructive patients. needs patient, breast discuss sensation The surgeons are of with meet the about opinion stakeholder choose to surgeons continue and to working healthcare discuss exciting will a plastic leading We group of and for repair the this collaborate new to application nerve for group potential
clinical cut nerves result these surgeon neuroma surgery transect the have repair the pain joint data reduce they resulting selection In damage Unfortunately, number total painful fibers to of repair patient a of assessing shown that Periodically as also called form the the a and replacement. transected are proper injuries pain the had and We has function. to painful surgeon now with of the a tangle restore of of in because a the nerve involve nerves a joint Recent out that can neuroma. has a to nerve nerve nerves. painful again. accessing joint patient nerve the gap orthopedic to
to Our are we patterns and referral to customers. that orthopedic current develop ways injuries the believe are these and patients that equipped surgeons not. surgeons current bring address to customer our in these plastic We of have opportunity awareness base orthopedic hand
Analyst applications pursuing announce November on are Day which at Investor of the XX. and We will upcoming expanded we our
Before that highlight want great Pete, I the I was to AxoGen. to quarter again turn a over call QX for
We strategic by continued execute and increased by over initiatives our with against revenue million to $XX gross to so doing margins we XX% XX%.
Our strong year-to-date was revenue growth. year-over-year representing million XX.X XX% at
society of adoption education at our repair in new current at are programs portfolio and nerve increasing on areas. focus interactions educational solutions our and portfolio professional awareness successful and experiencing for in demonstrating applications the applying Surgeons continued We awareness surgical our surgeon. are AxoGen meetings an of and
are towards markets symptomatic joint injuries potential and breast of total We expansion the in making neurotization replacement. to repair investments related reconstruction nerve
progress pleased our long-term and continue sustainable with to with the repair to develop are the market We opportunity drive nerve emerging growth. and
Now I'll Pete? over turn Pete. call the to
